Lenalidomide in 5q minus myelodysplastic syndrome: how long is enough?

被引：4

作者：

Duerr, Donat ^{[1
]}

Siciliano, Raffaele Daniele ^{[1
]}

Hummel, Yvonne ^{[1
]}

O'Meara, Alix ^{[1
]}

Hirschi, Anita ^{[1
]}

Burkhard, Roger ^{[1
]}

Honegger, Hanspeter ^{[1
]}

机构：

[1] Stadtspital Triemli, CH-8063 Zurich, Switzerland

来源：

ANNALS OF HEMATOLOGY | 2010年 / 89卷 / 01期

关键词：

DELETION; MANAGEMENT; DEL(5Q);

D O I：

10.1007/s00277-009-0775-x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：105 / 106

页数：2

共 7 条

[1] Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes [J].

Giagounidis, Aristoteles ;

Fenaux, Pierre ;

Mufti, Ghulam J. ;

Muus, Petra ;

Platzbecker, Uwe ;

Sanz, Guillermo ;

Cripe, Larry ;

Von Lilienfeld-Toal, Marie ;

Wells, Richard A. .

ANNALS OF HEMATOLOGY, 2008, 87 (05) :345-352

[2] Lenalidomide in the context of complex karyotype or interrupted treatment:: case reviews of del(5q) MDS patients with unexpected responses [J].

Giagounidis, Aristoteles A. N. ;

Haase, Sabine ;

Heinsch, Michael ;

Goehring, Gudrun ;

Schlegelberger, Brigitte ;

Aul, Carlo .

ANNALS OF HEMATOLOGY, 2007, 86 (02) :133-137

[3] The role of lenalidomide in the management of myelodysplasia with del 5q [J].

Kelaidi, Charikleia ;

Eclache, Virginie ;

Fenaux, Pierre .

BRITISH JOURNAL OF HAEMATOLOGY, 2008, 140 (03) :267-278

[4] Efficacy of lenalidomide in myelodysplastic syndromes [J].

List, A ;

Kurtin, S ;

Roe, DJ ;

Buresh, A ;

Mahadevan, D ;

Fuchs, D ;

Rimsza, L ;

Heaton, R ;

Knight, R ;

Zeldis, JB .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (06) :549-557

[5] Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion [J].

List, Alan ;

Dewald, Gordon ;

Bennett, John ;

Giagounidis, Aristotle ;

Raza, Azra ;

Feldman, Eric ;

Powell, Bayard ;

Greenberg, Peter ;

Thomas, Deborah ;

Stone, Richard ;

Reeder, Craig ;

Wride, Kenton ;

Patin, John ;

Schmidt, Michele ;

Zeldis, Jerome ;

Knight, Robert .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (14) :1456-1465

[6] The response to lenalidomide of myelodysplastic syndrome patients with deletion del(5q) can be sequentially monitored in CD34+ progenitor cells [J].

Mohr, Brigitte ;

Oelschlaegel, Uta ;

Thiede, Christian ;

Stewart, Michelle Meredyth ;

Ehninger, Gerhard ;

Platzbecker, Uwe .

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 (03) :430-431

[7] Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1-risk myelodysplastic syndromes with karyotypes other than deletion 5q [J].

Raza, Azra ;

Reeves, James A. ;

Feldman, Eric J. ;

Dewald, Gordon W. ;

Bennett, John M. ;

Deeg, Joachim ;

Dreisbach, Luke ;

Schiffer, Charles A. ;

Stone, Richard M. ;

Greenberg, Peter L. ;

Curtin, Peter T. ;

Klimek, Virginia M. ;

Shammo, Jamile M. ;

Thomas, Deborah ;

Knight, Robert D. ;

Schmidt, Michele ;

Wride, Kenton ;

Zeldis, Jerome B. ;

List, Alan F. .

BLOOD, 2008, 111 (01) :86-93

← 1 →